NCT06248567

Pharmacokinetics of ZSP1273 in Participants With Severe Kidney Disease

A Phase I Single Dose, Non-Randomised, Open-Label, Parallel Group Study to Investigate the Effect of Severe Kidney Impairment on the Pharmacokinetics, Safety and Tolerability of ZSP1273

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 16 (actual)
• Sponsor: Guangdong Raynovent Biotech Co., Ltd · Industry
• Sex: All
• Age: 15 Years – 65 Years
• Healthy volunteers: Accepted

Summary

This study will assess the effect of severe kidney impairment on the pharmacokinetics (PK), safety and tolerability of ZSP1273.

Conditions

• Kidney Impairment

Interventions

Type	Name	Description
DRUG	ZSP1273	Oral

Timeline

• Start date: 2024-01-15
• Primary completion: 2024-04-30
• Completion: 2024-05-30
• First posted: 2024-02-08
• Last updated: 2025-03-19

Locations

1 site across 1 country: China